Selectquote, INC

SelectQuote, Inc. announced its fourth quarter and full fiscal year 2026 results, highlighting a significant improvement in operating cash flow and strong performance in its Senior segment, while also reporting a net loss for the quarter and a decrease in full-year Adjusted EBITDA.

SelectQuote, Inc. announced its third quarter fiscal year 2026 financial results, showcasing revenue growth and improved profitability.

SelectQuote, Inc. received a notice from the NYSE for non-compliance due to its common stock trading below $1.00 for 30 consecutive days, initiating a six-month cure period.

SelectQuote, Inc. reported a 12% increase in consolidated revenue for the second quarter of fiscal year 2026, reaching $537.1 million, but revised its full-year guidance downwards due to partner-driven headwinds.

SelectQuote, Inc. announced a new $415 million credit facility, comprising a $325 million term loan and a $90 million revolving credit facility, significantly extending its debt maturity to January 2031 and enhancing liquidity.

SelectQuote, Inc. announced the successful outcome of its 2025 Annual Meeting of Stockholders, with all management-backed proposals passing.

SelectQuote reports a 12% revenue increase for the six months ended December 31, 2025, driven by its Healthcare Services segment, alongside a significant debt refinancing and ongoing legal challenges.

SelectQuote, Inc. reported a wider net loss attributable to common shareholders in Q1 2026, driven by a significant decline in its Senior insurance segment despite growth in Healthcare Services.

SelectQuote's Q3 2025 results reveal a revenue increase driven by pharmacy services, overshadowed by a DOJ investigation and a decline in Senior segment performance.

SelectQuote, Inc. reports a rise in revenue and income from operations for the quarter ended December 31, 2024, driven by growth in its Senior and Healthcare Services segments.

SelectQuote's first quarter of fiscal year 2025 shows a 26% increase in total revenue, primarily driven by a 61% surge in pharmacy revenue, while the company navigates ongoing financial challenges.

SelectQuote's Q3 2024 results show revenue growth driven by pharmacy sales, but also reveal ongoing losses and debt restructuring efforts.

SelectQuote, Inc. files its annual report, detailing its capital stock structure, anti-takeover provisions, and corporate governance, alongside financial performance and risk factors.

SelectQuote, a leading insurance distributor, pivots to healthcare services, achieving net income in fiscal year 2025 despite a decline in its core Senior insurance segment.

SelectQuote, Inc. released its annual 10-K filing, detailing its business model, financial performance, and strategic outlook for the coming year.

Ryan Moore Clement, Chief Financial Officer of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

Sarah Taylor Anderson, (See Remarks) of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

Stephanie D. Fisher, Chief Accounting Officer of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

Timothy Robert Danker, CHIEF EXECUTIVE OFFICER and a Director of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

Joshua Brandon Matthews, President, SelectQuote Senior of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

Robert Clay Grant, PRESIDENT of SelectQuote, Inc., reported multiple transactions in common stock on August 1, 2026.

SelectQuote, Inc. has filed a definitive proxy statement with the SEC, indicating an upcoming shareholder meeting.

SelectQuote, Inc. announces robust fiscal year 2025 financial results, including significant revenue growth and a strategic capital raise, ahead of its 2025 Annual Meeting of Stockholders.

SelectQuote, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

SelectQuote, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on November 12, 2024, to vote on director elections, auditor ratification, and executive compensation.

Morgan Stanley filed an amended Schedule 13G to clarify its beneficial ownership in SelectQuote, Inc., adjusting for warrant exercise limitations.

Morgan Stanley has reported a 5.6% beneficial ownership stake in SelectQuote, Inc.'s common stock, held for passive investment purposes.